There is an increased risk that these devices will not provide audible alerts for low or high blood glucose levels. The FDA has ruled that this is a Class I recall, highlighting the safety risks associated with missed alerts.

"Using AI for tasks like CAC detection can help shift medicine from a reactive approach to the proactive prevention of disease," one researcher said.

The company's SSi Mantra 3 robotic surgery system has already gained regulatory approvals in several countries. FDA approval is anticipated by late 2025 or early 2026.

The Pearl, a new innovation hub in North Carolina, will soon be home to the first training center of its kind. Many of the advanced technologies on hand will be designed by Medtronic.

Janet Wei, MD, examined the key differences between men and women when it comes to cardiovascular disease. These differences, she said, highlight why female patients need their very own treatment guidelines.

The three-day event is now in its second year. Each day will feature late-breaking clinical trials focused on a different heart valve.

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

The San Diego-based startup gained FDA approval for its Hotwire RF guidewire in 2024. The technology has already been used to perform hundreds of heart procedures.

Dean J. Kereiakes, MD, was left paralyzed after battling severe orthopedic issues for his entire career. Back in the cath lab after a long recovery, he is now stressing the importance of workplace safety among interventional cardiologists.

From new drug therapies and imaging technologies to updated prevention strategies, nearly every aspect of cardiovascular care is starting to embrace the value of coronary inflammation evaluations. Paul Ridker, MD, MPH, discussed the trend in a new interview.

Cardiovascular Associates of America and cardiologist-founded HybridChart are now working together in a move designed to deliver value-based care to heart patients.

Janmarie Lanzo is charged with conspiracy to violate the Food, Drug, and Cosmetic Act and defraud the FDA, according to the indictment. 

Lines included in the kits were misassembled and could result in a botched blood transfusion. Due to the risk of serious injury or death, the recall has been designated as Class I.